Drugs / Androtriol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06679322 | Oct 2024 → Sep 2025 overdue | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Androtriol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06679322 ↗ |
| Route | Intravenous | “Participants will receive a low-dose Androtriol injection (100 mg BID), a high-dose Androtriol injection (300 mg BID), or a placebo intravenously within 24 hours of stroke onset.” NCT06679322 ↗ |